
    
      This is a phase Ib/II, single-center, open-label study designed to assess the safety,
      tolerability, pharmacokinetics, and biologic efficacy of ABT-510 (thrombospondin).
      Participants will be patients with incurable head and neck cancer.

      Patients will begin at a fixed dose level of thrombospondin subcutaneously twice daily.
      Cycles of treatment are 28 days (4 weeks). Patients will be treated with thrombospondin until
      progression of tumor or toxicity.
    
  